Johnson & Johnson launches Dual Energy THERMOCOOL SMARTTOUCH SF cardiac ablation platform in Europe

Johnson & Johnson

JNJ

0.00

Johnson & Johnson launched the Dual Energy THERMOCOOL SMARTTOUCH SF Platform in Europe, broadening its cardiac ablation portfolio in a fast-growing atrial fibrillation market.
The system positions the group with a differentiated dual-energy offering, strengthening competitiveness as rivals push newer ablation modalities across Europe.
Launch leverages an established installed base and workflow familiarity, supporting faster adoption and pull-through for the company’s broader electrophysiology ecosystem.
Clinical data cited 86.9% effectiveness at 12 months in a first-in-human study subgroup, supporting commercialization and physician confidence.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.